jRCT2080223538已完成3 期
A Phase III,Multicenter,Randomized,Double-Blind,Placebo-Controlled,Parallel-Group,Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 750
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter,randomized,double-blind,placebo-controlled,parallel-group
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 50age old over 至 85age old under（—）
- 性别
- All
入选标准
- •Meet NIA-AA core clinical criteria for probable AD dementia or prodromal AD
- •Having mild symptomatology,as defined by a screening MMSE score of 22 points and higher,and CDR-GS of 0.5 or 1.0
排除标准
- •Any evidence of a condition other than AD that may affect cognition
- •Meet the exclusion criteria of MRI at screening
结局指标
主要结局
-
safety efficacy Observation/Examination
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A study to learn how BAY2927088 is taken up and handled by the body in healthy male participantsCTIS2022-502771-38-00Bayer AG8
进行中（未招募）
1 期
A study to compare how much of the study treatment finerenone gets into the blood when the same amount is taken in one and in two tablets in healthy male participantsCTIS2022-502385-24-00Bayer AG60
招募中
1 期
A study to learn about the taste of Vericiguat given in liquid form in healthy male participants aged 18 to 45 yearsCTIS2023-508447-52-00Bayer AG20
进行中（未招募）
1 期
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.MedDRA version: 20.1Level: LLTClassification code: 10054109Term: Non-proliferative diabetic retinopathy Class: 10015919MedDRA version: 23.1Level: PTClassification code: 10064848Term: Chronic kidney disease Class: 100000004857Chronic kidney diseaseCTIS2024-510856-11-00Bayer AG15
进行中（未招募）
1 期
First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expressionMedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2023-507486-26-00Bayer Consumer Care AG135